Overview

Study Evaluating Genotypes Using Lucentis

Status:
Terminated

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

Details

Lead Sponsor:

University of Utah

Collaborator:

Genentech, Inc.

Treatments:

Ranibizumab